Article

Angiogenic Lung Factor: New Predictive Tool in PAH?

Where NTProBNP falls short, hepatoma derived growth factor may more than succeed.

 

Pulmonary microvascular remodeling contributes significantly to the development of pulmonary arterial hypertension. Authors of the current study hypothesized that levels of a circulating angiogenic factor could be used to predict disease severity and survival.

 

Serum hepatoma derived growth factor (HDGF) is an angiogenic factor involved in lung remodeling and secreted by pulmonary endothelial cells that may prove a more reliable measure of risk than NTProBNP in persons with pulmonary arterial hypertension.

 

 

HDGF levels were significantly elevated in both PAH cohorts; elevated HDGF linked to significantly lower exercise tolerance, worse NYHA functional class, higher levels of NTproBNP.

 

 

Threshold value of HDGF to distinguish PAH from healthy: Sensitivity 73, specificity 85, positive predictive value 76%, negative predictive value 89%.

Source: Yang J, Nies MK, Fu Z, et al. Hepatoma derived growth factor predicts disease severity and survival in pulmonary arterial hypertension. Am J Respir Crit Care Med.  Published online June 2 2016. 

 

 

Related Videos
Experts' Perspectives: Top Stories in Cardiology for 2024
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Nathan D. Wong, MD, PhD: Growing Role of Lp(a) in Cardiovascular Risk Assessment | Image Credit: UC Irvine
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management  | Image Credit: Emory University
Laurence Sperling, MD: Multidisciplinary Strategies to Combat Obesity Epidemic | Image Credit: Emory University
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orly Vardeny, PharmD: Finerenone for Heart Failure with EF >40% in FINEARTS-HF | Image Credit: JACC Journals
Matthew J. Budoff, MD: Impact of Obesity on Cardiometabolic Health in T1D | Image Credit: The Lundquist Institute
Matthew Weir, MD: Prioritizing Cardiovascular Risk in Chronic Kidney Disease | Image Credit: University of Maryland
© 2025 MJH Life Sciences

All rights reserved.